ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: 1731 • ACR Convergence 2020

    Development of a Disease Activity Index for Rheumatoid Arthritis Patients Using the HandScan

    Maxime Verhoeven1, Paco Welsing1, Janneke Tekstra1, Jacob van Laar1, Floris Lafeber1, Johannes Jacobs1 and Anton Westgeest2, 1UMC Utrecht, Utrecht, Netherlands, 2Máxima MC Eindhoven, Eindhoven, Netherlands

    Background/Purpose: Disease activity in rheumatoid arthritis (RA) patients is usually measured by an index like DAS28,1 a composite measure consisting of 28 swollen and/or tender…
  • Abstract Number: 2031 • ACR Convergence 2020

    Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis

    Augusta Ortolan1, Victoria Navarro-Compán2, Alexandre Sepriano3, Robert Landewé4, Désirée van der Heijde5 and Sofia Ramiro6, 1Leiden University Medical Center, Padova, Italy, 2Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, 3Leiden University Medical Center, Portela Loures, Portugal, 4Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, 5Leiden University Medical Center, Leiden, Netherlands, 6Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: Several disease activity response and status criteria are used to assess treatment efficacy in RCTs in axial spondyloarthritis (axSpA). Response criteria include: the Assessment…
  • Abstract Number: 0255 • ACR Convergence 2020

    Effect of Removing Haemolytic and Gastrointestinal Activity from the Operational Definition of the Lupus Low Disease Activity State – Implications for Use as a Trial Endpoint

    Vera Golder1, Rangi Kandane-Rathnayake1, Molla Huq2, Worawit Louthrenoo3, Shue Fen Luo4, Yeong-Jian Wu5, Aisha Lateef6, Sargunan Sockalingam7, Sandra Navarra8, Leonid Zamora9, Laniyati Hamijoyo10, Yasuhiro Katsumata11, Masayoshi Harigai12, Madelynn Chan13, Sean O'Neill14, Fiona Goldblatt15, Chak Sing Lau16, Zhanguo Li17, Alberta Hoi18, Mandana Nikpour19 and Eric Morand20, 1Monash University, Clayton, Victoria, Australia, 2University of Melbourne, Melbourne, Victoria, Australia, 3Maharaj Nakorn Chiangmai, Muang, Thailand, 4Chang Gung Memorial Hospital-Linkou, Taoyuan, Taipei, Taiwan (Republic of China), 5Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), 6National University Hospital, Singapore, Singapore, 7University of Malaya, Kuala Lumpur, Malaysia, 8University of Santo Tomas, Manila, Philippines, 9University of Santo Thomas, Manila, Philippines, 10University of Padjadjaran, Bandung, Indonesia, 11Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 12Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, 13Tan Tock Seng Hospital, Singapore, Singapore, 14Sydney University, Sydney, Australia, 15Royal Adelaide Hospital, Adelaide, Australia, 16Hong Kong University, Hong Kong, Hong Kong, 17Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic), 18Monash University, Melbourne, Victoria, Australia, 19The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia, 20Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

    Background/Purpose: The Lupus Low Disease Activity State (LLDAS) has recently undergone prospective longitudinal validation in a multinational cohort, demonstrating the association of attaining LLDAS with…
  • Abstract Number: 0514 • ACR Convergence 2020

    Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study

    Kaitlin Quinn1, Himanshu Dashora2, Mark Ahlman3, Elaine Novakovich2 and Peter C. Grayson2, 1Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, 2Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, 3National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD

    Background/Purpose: Two randomized controlled trials have demonstrated the clinical efficacy of tocilizumab for treatment of giant cell arteritis (GCA) (1,2).  In these trials, response to…
  • Abstract Number: 0909 • ACR Convergence 2020

    Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study

    Iain McInnes1, Philip Mease2, Dafna Gladman3, Laura Coates4, Peter Nash5, Alexis Ogdie6, Frank Behrens7, Philippe Goupille8, Arthur Kavanaugh9, Ruvie Martin10, Erhard Quebe-Fehling11 and Corine Gaillez11, 1Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 3Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 4University of Oxford, Oxford, United Kingdom, 5School of Medicine Griffith University, Brisbane, Queensland, Australia, 6University of Pennsylvania, Philadelphia, PA, 7CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, 8CHU Tours, department of rheumatology, Tours, France, 9Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, 10Novartis Pharmaceuticals Corporation, East Hanover, NJ, 11Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: Recent EULAR recommendations propose that treatment of psoriatic arthritis (PsA) should seek remission (REM) or alternatively low disease activity (LDA) by regular disease activity…
  • Abstract Number: 1585 • ACR Convergence 2020

    Lessons Learned Through Rapid Quality Improvement for Telehealth Implementation in an Academic Rheumatology Practice During the COVID-19 Pandemic

    Julie Thomas1, Dorota Lebiedz-Odrobina1, Kyle Register1, Francesca Ferrara1, Danielle Barlow1, Alicia Riddle1 and Karla Miller2, 1University of Utah, Salt Lake City, UT, 2Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT

    Background/Purpose: The COVID-19 pandemic created an urgent need for access to care while preserving patient safety through social distancing. Prior to the pandemic, patients were…
  • Abstract Number: 1743 • ACR Convergence 2020

    Perioperative Steroids in Rheumatoid Arthritis Patients Having Total Joint Replacements: Help or Harm?

    Tariq Chukir1, Susan Goodman2, Haley Tornberg3, Huong Do4, Charlene Thomas5, Alana Sigmund3, Peter Sculco6, Bella Mehta6, Linda Russell6, Mark Figgie2 and Emily Stein7, 1Weill Cornell Medicine and New York Presbyterian Hospital, New York, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, New York, 4Hospital for Special Surgery, New York, NY, 5Weill Cornell Medicine, New York, 6Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 7Endocrine Service, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY

    Background/Purpose: Optimal perioperative glucocorticoids (GC) dosing for rheumatoid arthritis (RA) patients on chronic GCs undergoing total joint replacement is unknown.  Ideal GC dosing prevents perioperative…
  • Abstract Number: 0263 • ACR Convergence 2020

    Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus

    Stephanie Florez-Pollack1, Syed Rizvi2, Benjamin Chong2 and Linda Hynan2, 1University of Pennsylvania, PHILADELPHIA, PA, 2University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Cutaneous lupus erythematosus (CLE) is a photosensitive skin disorder that can occur with systemic lupus erythematosus. As CLE often fluctuates in disease activity, little…
  • Abstract Number: 0518 • ACR Convergence 2020

    The Impact of Large Vessel Vasculitis of the Axillary Artery on Cumulative Glucocorticoid Dose and Relapse Rate in Giant Cell Arteritis

    Philipp Bosch1, Christian Dejaco2, Wolfgang Schmidt3, Andreas Krause3, Kenny-Davis Schlüter3, Gudrun Pregartner4 and Valentin Schaefer5, 1Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, 2Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria and Rheumatology Service, Hospital of Bruneck, Bruneck, Italy, Bruneck, Italy, 3Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, 4Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria, Graz, Austria, 5Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany

    Background/Purpose: Prognostic markers for clinical outcomes in giant cell arteritis (GCA) are urgently needed. While large vessel GCA (LV-GCA) has been associated with higher glucocorticoid…
  • Abstract Number: 0941 • ACR Convergence 2020

    MDHAQ/RAPID3 (multidimensional Health Assessment Questionnaire/routine Assessment of Patient Index Data) Levels Are Elevated in Rheumatology Patients Who Meet 2011 Fibromyalgia (FM) or MDHAQ/FAST3 (fibromyalgia Assessment Screening Tool) Criteria

    Juan Schmukler1, Tengfei Li2, Kyle Schroeder3 and Theodore Pincus3, 1Mount Sinai Hospital Chicago, IL, Chicag, IL, 2Georgetown University, Washigton, 3Rush University Medical Center, Chicago, IL

    Background/Purpose: RAPID3 (routine assessment of patient index data) on an MDHAQ (multiple multidimensional health assessment questionnaire) was developed initially to assess patients with rheumatoid arthritis…
  • Abstract Number: 1596 • ACR Convergence 2020

    Coproduction of Care for Veterans with RA: Improving Elicitation and Documentation of Patient Goals

    Swathi Reddy1, Kyawt Shwin1, Rashmi Arora1, Sarah Homann2, Lisa Johnson3, Yusuf Chao4, Aricca Van Citters3, Brant Oliver5, Guy Eakin6, Eugene Nelson3, Andreas Reimold1 and Salahuddin Kazi1, 1Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX, 2Veterans Affairs Tennessee Valley Healthcare System / Vanderbilt University Medical Center, Nashville, TN, 3The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, 4UT Southwestern Medical Center, Dallas, TX, 5The Dartmouth Institute for Health Policy & Clinical Practice / Veterans Affairs National Quality Scholars Fellowship in Healthcare Quality & Safety, Lebanon, NH, 6Arthritis Foundation, Atlanta, GA

    Background/Purpose: Coproduction of healthcare services offers a pathway to increase patient engagement in care. Patients and clinicians coproduce care by working together to: (1) co-assess…
  • Abstract Number: 1851 • ACR Convergence 2020

    Different Disease Activity Trajectories in Early Axial Spondyloarthritis Lead to Significantly Different Long-term Outcomes : A Cluster-based Analysis of the DESIR Cohort

    Benattar Leslie1, Anna Molto2, Laure Gossec3 and Resche Rigon Matthieu4, 1Cochin Hospital, Paris, Paris, Ile-de-France, France, 2Rheumatology Department, Cochin Hospital, APHP, Paris, France, Paris, France, 3Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, 4INSERM (UFR 1153), Saint Louis Hospital, Paris, Paris, France

    Background/Purpose:  AxSpA is a heterogeneous disease, leading to different treatment and follow-up modalities depending on the presentation, along with other elements (socio-economic, gender, etc..). In a…
  • Abstract Number: 0271 • ACR Convergence 2020

    External Validation of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a Predictor of Mortality and Organ Damage Accrual in Systemic Lupus Erythematosus

    Alicia Malone1, Alexandra Legge1 and John Hanly1, 1Dalhousie University, Halifax, NS, Canada

    Background/Purpose: Using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, a frailty index (FI) was recently developed as a measure of susceptibility…
  • Abstract Number: 0542 • ACR Convergence 2020

    Examining the Long-Term and Short-Term Day-To-Day Pain Variability in Inflammatory and Non-Inflammatory Rheumatic and Musculoskeletal Diseases Using Multilevel and Markov Transition Models: Cloudy with a Chance of Pain, a National U.K. Smartphone Study

    Huai Leng Pisaniello1, Mark Lunt2, John McBeth3 and William Dixon2, 1University of Adelaide, Kidman Park, South Australia, Australia, 2Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom, 3University of Manchester, Manchester, United Kingdom

    Background/Purpose: Chronic pain is common in rheumatic and musculoskeletal diseases (RMDs), yet the patterns and the extent of variability over time are poorly understood. Real-time…
  • Abstract Number: 0987 • ACR Convergence 2020

    Efficacy and Safety of Iberdomide in Patients with Active Systemic Lupus Erythematosus: 24-Week Results of a Phase 2, Randomized, Placebo-Controlled Study

    Joan Merrill1, Victoria Werth2, Richard Furie3, Ronald van Vollenhoven4, Milan Petronijevic5, Benito Velasco Zamora6, Maria Majdan7, Fedra Irazoque-Palazuelos8, Michael Weiswasser9, Shimon Korish9, Peter Schafer9, Zhaohui Liu9, Allison Gaudy9, Nataliya Agafonova9 and Nikolay Delev9, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 3Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 4Amsterdam University Medical Centers, Amsterdam, Netherlands, 5Military Medical Academy, Belgrade, Serbia, 6Instituto CER S.A., Buenos Aires, Argentina, 7Medical University of Lublin and Samodzielny Publicnzy Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland, 8Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, 9Bristol Myers Squibb, Princeton

    Background/Purpose: Iberdomide is a high-affinity cereblon ligand that promotes ubiquitination and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors linked to the genetic…
  • « Previous Page
  • 1
  • …
  • 33
  • 34
  • 35
  • 36
  • 37
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology